Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N.

Slides:

Advertisements

Similar presentations

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Advertisements

All-Cause and Cause-Specific Mortality in Patients with Psoriasis in Taiwan: A Nationwide Population-Based Study Meng-Sui Lee, Yi-Chun Yeh, Yun-Ting.

Obesity, Waist Circumference, Weight Change, and Risk of Incident Psoriasis: Prospective Data from the HUNT Study Ingrid Snekvik, Catherine H. Smith,

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis Zenas Z.N. Yiu, Lesley S. Exton, Zarif.

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review Nolan J. Maloney, BS, Lisa D. Hisaw,

Establishing an Academic–Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy Christopher E.M. Griffiths,

Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK Katrina.

Expanding Our Understanding of Human Skin Aging

Skin-Derived Vitamin D3 Protects against Basal Cell Carcinoma

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists.

Research Techniques Made Simple: Understanding Network Meta-Analysis

A Score with a VESted Interest in Vitiligo

Michael L. Frisoli, John E. Harris

Partik Singh, BA, Jonathan I. Silverberg, MD, MPH, PhD

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Research Techniques Made Simple: Workflow for Searching Databases to Reduce Evidence Selection Bias in Systematic Reviews Laurence Le Cleach, Elizabeth.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists.

Clinical Snippets Journal of Investigative Dermatology

Fnu Nutan, Alex G. Ortega-Loayza

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

Aaron M. Drucker, Patrick Fleming, An-Wen Chan

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Amy C. Foulkes, David S. Watson, Daniel F. Carr, John G

Luigi Naldi Journal of Investigative Dermatology

The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031 David C.

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Databases for Clinical Research

Joanne E. Sordillo, Peter Kraft, Ann Chen Wu, Maryam M. Asgari

Research Techniques Made Simple: Network Meta-Analysis

Clinical Snippets Journal of Investigative Dermatology

Research Techniques Made Simple: Cost-Effectiveness Analysis

An Unexpected Role for TRPV4 in Serotonin-Mediated Itch

Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases Megan H. Noe, Daniel B. Shin, Rebecca A. Hubbard,

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis Eleanor J. Samarasekera, Julie M. Neilson, Richard.

Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria Keith C.P. Wu, Zarif K. Jabbar-Lopez Journal.

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength Rachael J. Thorneloe,

Tamar Nijsten Journal of Investigative Dermatology

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

More Than Many: How to Manage the Most Frequent Cancer?

Teledermatology in China: History, Current Status, and the Next Step

Minutes of the Board of Directors Meeting

Adalimumab in Psoriasis: How Much Is Enough?

Journal of Investigative Dermatology

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association.

Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis Chloé Théréné, Emilie Brenaut, Thomas Barnetche,

Clinical Snippets Journal of Investigative Dermatology

Sigrun A.J. Schmidt, Serigne Lo, Loes M. Hollestein

Research Techniques Made Simple: Itch Measurement in Clinical Trials

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology Amy C. Foulkes, David S. Watson, Christopher E.M. Griffiths, Richard B. Warren,

HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program Katherine Li, C. Chris Huang, Bruce Randazzo,

Society for Investigative Dermatology 2010 Meeting Minutes

Journal of Investigative Dermatology

Erratum Journal of Investigative Dermatology

Research Snippets Journal of Investigative Dermatology

Reviewer Acknowledgment

BJD Editor’s Choice Journal of Investigative Dermatology

Research Snippets from the British Journal of Dermatology

Journal of Investigative Dermatology

Billy R. Wooten Journal of Investigative Dermatology

Journal of Investigative Dermatology

Journal of Investigative Dermatology

Journal of Investigative Dermatology

The Environment and Human Health

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian.

Frances L. Shaw, Kieran T. Mellody, Stephanie Ogden, Rebecca J

The mTSS individual-patient change from baseline to Week 52 cumulative probability plot (observed data). The mTSS individual-patient change from baseline.

Presentation transcript:

Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu, Victoria Ward, Lesley S. Exton, M. Firouz Mohd Mustapa, Eleanor Samarasekera, A. David Burden, Ruth Murphy, Caroline M. Owen, Richard Parslew, Vanessa Venning, Richard B. Warren, Catherine H. Smith Journal of Investigative Dermatology Volume 137, Issue 12, Pages 2644-2646 (December 2017) DOI: 10.1016/j.jid.2017.07.848 Copyright © 2017 The Authors Terms and Conditions

Figure 1 Efficacy compared with tolerability at weeks 12 to 16 based on Figure 1 from Reich et al. Risk differences from Table 1 of Jabbar-Lopez et al. (2017). ADA, adalimumab; ETA, etanercept; INF, infliximab; IXE, ixekizumab; MTX, methotrexate; PBO, placebo; SEC, secukinumab; UST, ustekinumab. Journal of Investigative Dermatology 2017 137, 2644-2646DOI: (10.1016/j.jid.2017.07.848) Copyright © 2017 The Authors Terms and Conditions